PDS Biotechnology nanotech-based immunotherapy gets FDA nod
‎Singapore: US-based PDS Biotechnology's Versamune nanotechnology vaccine platform recieved approval from FDA to be evaluated in human patients.
Versamune is a nanotechnology-based immune modulating technology, which acts by a novel mechanism to prime and activate the immune system in order to recognize specific diseased cells and disease causing agents. The technology is unique in its multiple-mode-of-action enabling simple and effective disease-targeting vaccines and immunotherapies to be developed.
PDA is also developing PDS0101 is a first-in-class immunotherapy to treat cancers and diseases caused by infection with the human papillomavirus such as cervical cancer, head and neck cancer and cervical intraepithelial neoplasia. Dr Frank Bedu-Addo, president and CEO, said that the preclinical efficacy and safety data demonstrated eradication of the tumors without any of the safety drawbacks that are typical of the current immunotherapy technologies.
PDS0101 is designed to prime the immune system to recruit cells of the body's own immune system to specifically recognize, target and kill the cancer cells. PDS0101 is also designed to reduce the population of certain immune suppressive cells which prevent our immune systems from detecting and attacking the cancer cells.
Dr Bedu-Addo said that, "Should the preclinical results be replicated in the clinical setting, this will be a giant leap forward in the development of safe and effective cancer therapies."
